Santen Pharmaceutical Co., Ltd.
SNPHY
Rank in Stocks
#3793
Santen Pharmaceutical Co., Ltd. is a global enterprise engaged in the research,... Santen Pharmaceutical Co., Ltd. is a global enterprise engaged in the research, development, manufacturing, and marketing of both pharmaceutical products and medical devices. The company's primary focus lies in ophthalmic solutions, addressing a variety of eye conditions. Its pipeline for glaucoma and ocular hypertension includes several key assets: DE-111, currently in Phase III clinical trials; DE-117, available for sale in Japan; DE-126, progressing through Phase IIb trials; DE-128, which is on the market in Europe and undergoing Phase II/III trials in the United States; and DE-130A, also in Phase III development. Beyond glaucoma, Santen's offerings extend to other ocular ailments. It provides DE-114A for allergic conjunctivitis and DE-076C for vernal keratoconjunctivitis. Furthermore, DE-109 is in Phase III clinical trials for the treatment of uveitis. The company is also active in addressing myopia with DE-127, currently in Phase II/III trials in Japan and Phase III in other Asian markets, alongside STN1013400, which is in Phase I trials. For dry eye, Santen offers DE-089C, which has successfully concluded its Phase III clinical trials. In addition to its prescription portfolio, the company produces and sells various over-the-counter (OTC) pharmaceutical products. Founded in 1890 under the name Santendo Pharmaceutical Co., Ltd., the company rebranded to its current name, Santen Pharmaceutical Co., Ltd., in 1958. It is headquartered in Osaka, Japan.
Share Price
$12.67
Last synced: 2026-11-09
Market Cap
$4.14B
Change (1 day)
6.03%
Change (1 year)
27.46%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Santen Pharmaceutical Co., Ltd. (SNPHY)
Category
Healthcare
EPS for Santen Pharmaceutical Co., Ltd. (SNPHY)
EPS as of June 2026 TTM: $0.77
According to Santen Pharmaceutical Co., Ltd.'s latest financial reports, its current EPS (TTM) is $0.77. At the end of 2025 the company had an EPS of $0.69, an increase over its 2024 EPS of $0.48.
EPS history for Santen Pharmaceutical Co., Ltd. from 2005 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.77 | 11.84% |
| 2025 | $0.69 | 44.58% |
| 2024 | $0.48 | -265.11% |
| 2023 | $-0.29 | -151.98% |
| 2022 | $0.56 | 262.11% |
| 2021 | $0.15 | -71.94% |
| 2020 | $0.55 | -22.35% |
| 2019 | $0.71 | -13.21% |
| 2018 | $0.82 | 71.74% |
| 2017 | $0.48 | -58.52% |
| 2016 | $1.15 | 136.32% |
| 2015 | $0.49 | 4.73% |
| 2014 | $0.46 | 11.45% |
| 2013 | $0.42 | -12.47% |
| 2012 | $0.47 | -21.20% |
| 2011 | $0.60 | 27.89% |
| 2010 | $0.47 | 94.59% |
| 2009 | $0.24 | -17.40% |
| 2008 | $0.29 | 14.05% |
| 2007 | $0.26 | 0.63% |
| 2006 | $0.26 | 8.63% |
| 2005 | $0.24 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $30.89 | 3,902.85% |
US
|
|
| $6.60 | 755.25% |
US
|
|
| $5.83 | 655.47% |
US
|
|
| $0.98 | 26.99% |
US
|
|
| $18.54 | 2,302.75% |
CH
|
Questions about Santen Pharmaceutical Co., Ltd.'s earnings per share (EPS)
What is Santen Pharmaceutical Co., Ltd.'s earnings per share (EPS)?
Santen Pharmaceutical Co., Ltd.'s earnings per share (EPS) over the last twelve months is $0.77, as of Jun 2026.
What was Santen Pharmaceutical Co., Ltd.'s earnings per share (EPS) in 2025?
In 2025, Santen Pharmaceutical Co., Ltd.'s earnings per share (EPS) was $0.69, 43.75% more than in 2024 ($0.48).
How has Santen Pharmaceutical Co., Ltd.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Santen Pharmaceutical Co., Ltd.'s earnings per share (EPS) went from $0.55 to $0.69, an average growth of 4.64% a year.
How does Santen Pharmaceutical Co., Ltd.'s earnings per share (EPS) compare with similar companies?
Santen Pharmaceutical Co., Ltd.'s earnings per share (EPS) ($0.77) is lower than that of all 5 similar companies listed above. The highest among them is Eli Lilly and Company, with $30.89.